Draft PR Series C - Imvax
Interim results from the Phase 1b trial, which were presented at the American Association for Cancer Research Annual Meeting (AACR) in 2019, demonstrated treatment with IGV-001 outperformed standard of care with prolonged overall survival (OS) and progression-free survival (PFS) in patients with newly diagnosed GBM. ................
................
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.